UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033955
Receipt number R000038714
Scientific Title A Feasibility Clinical Trial of the Management of the Medically Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinsons Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System
Date of disclosure of the study information 2018/09/01
Last modified on 2020/03/02 18:18:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Feasibility Clinical Trial of the Management of the Medically Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinsons Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System

Acronym

PD002J

Scientific Title

A Feasibility Clinical Trial of the Management of the Medically Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinsons Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System

Scientific Title:Acronym

PD002J

Region

Japan


Condition

Condition

Medically Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinsons Disease

Classification by specialty

Neurology Neurosurgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications in subjects who are over 20 years of age and considered medication refractory with advanced idiopathic Parkinsons disease .

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications and considered medication refractory with advanced idiopathic Parkinsons disease.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Men and women, age 20 years and older
2. Subjects who are able and willing to give informed consent and able to attend all study visits through 24 Months
3. Subjects with a diagnosis of idiopathic PD by UK Brain Bank Criteria as confirmed by a movement disorder neurologist at the site
4. Levodopa responsive as defined by at least a 30% reduction in MDS-UPDRS motor subscale in the ON vs OFF medication state.
5. MDS UPDRS score of 30 in the meds OFF condition
6. Disabling motor complications of PD on optimum medical treatment characterized dyskinesia or motor fluctuations (MDS-UPDRS item 4.2 score of 2 or 3 in the meds ON condition)
7. Predominant disability from one side of the body.
8. Subjects should be on a stable dose of all PD medications for 30 days prior to study entry.
9. Subject is able to communicate sensations during the ExAblate Neuro procedure.

Key exclusion criteria

1. Hoehn and Yahr stage in the on medication state of 3 or greater
2. Presence of other central neurodegenerative disease suspected on neurological examination.
3. Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.
4. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia
5. Presence of significant cognitive impairment defined as score 21 Unstable psychiatric disease,
6. Subjects with significant depression as determined following a comprehensive assessment by a neuropsychologist.
7. Subjects exhibiting any behavior consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM 4 .
8. 9.Subjects with unstable cardiac status including.
10.Severe hypertension
11.Current medical condition resulting in abnormal bleeding and or coagulopathy
12.Receiving anticoagulant
13. Subjects with risk factors for intraoperative or postoperative bleeding as indicated
14. Patient with severely impaired renal function with estimated glomerular filtration rate
15. Subjects with standard contraindications for MR imaging
16. Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment.
17. History of intracranial hemorrhage
18. History of multiple strokes, or a stroke within past 6 months
19. Subjects with a history of seizures within the past year
20. Subjects with brain tumors
21. Subjects with intracranial aneurysms requiring treatment or arterial venous malformations requiring treatment.
22. Pregnancy or lactation.
23. All patients with severe premorbid risks3 4 MDS UPDRS Part1 2

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Tetsumasa
Middle name
Last name Kamei

Organization

Medical Corporation Tokushukai Shonanfujisawa Tokushukai hospital

Division name

neurology department

Zip code

2510041

Address

1-5-1,Kandai,Tsujido,Fujisawa,Kanagawa

TEL

0466-35-1177

Email

tetsumasakam@ctmc.jp


Public contact

Name of contact person

1st name Etsuko
Middle name
Last name Shimizu

Organization

Medical Corporation Tokushukai Shonanfujisawa Tokushukai hospital

Division name

Clinical Research Center

Zip code

2510041

Address

1-5-1,Kandai,Tsujido,Fujisawa,Kanagawa

TEL

0466-35-1177

Homepage URL


Email

etsuko.shimizu@tokushukai.jp


Sponsor or person

Institute

Medical Corporation Tokushukai Shonanfujisawa Tokushukai hospital

Institute

Department

Personal name



Funding Source

Organization

InSightec

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tokushuka group EC

Address

1-8-7 Koji-machi,Chiyoda-ku,Tokyo

Tel

0332634801

Email

etsuko.shimizu@tokushukai.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2016 Year 12 Month 08 Day

Date of IRB

2017 Year 01 Month 19 Day

Anticipated trial start date

2017 Year 01 Month 19 Day

Last follow-up date

2021 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 08 Month 30 Day

Last modified on

2020 Year 03 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038714


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name